Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics scheduled the release of topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 for May 7, 2026. The double-blind, placebo-controlled study targets participants with Duchenne Muscular Dystrophy who are exon 44 skipping amenable. Management will host an investor webcast and conference call at 8:30 a.m.
Key figures
- Drug Name
- ENTR-601-44
- Phase Of Trial
- Phase 1/2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.